The pharmacotherapy of depression with EPA
- Basant K Puri1
© Puri; licensee BioMed Central Ltd. 2009
Published: 22 April 2010
This lecture considers the pharmacotherapy of depression with EPA under the following headings:
First trial of pure EPA in severe treatment-resistant depression
Subsequent randomized double-blind placebo-controlled trials
Results obtained from our own group, including structural neuroimaging and 31-phosphorus neurospectroscopy findings, showing an association of EPA treatment of depression with a marked decrease in cerebral phosphodiesters, a marked increase in cerebral phosphomonoesters and reduced lateral ventricular volume, will also be presented.
This article is published under license to BioMed Central Ltd.